

ANSWERING REVIEWERS

December 29, 2013

Dear Editor,



Please find enclosed the edited manuscript in Word format (file name: *Helicobacter pylori* eradication one-week triple therapy with esomeprazole versus lansoprazole_WJG_02).

Title: A Comparative Study of Esomeprazole and Lansoprazole in Triple Therapy for Eradication of *Helicobacter pylori* in Japan

Author: Tsutomu Nishida, Masahiko Tsujii, Hirohisa Tanimura, Shusaku Tsutsui, Shingo Tsuji, Akira Takeda, Atsuo Inoue, Hiroyuki Fukui, Toshiyuki Yoshio, Osamu Kishida, Hiroyuki Ogawa, Masahide Oshita, Ichizo Kobayashi, Shinichiro Zushi, Makoto Ichiba, Naoto Uenoyama, Yuichi Yasunaga, Ryu Ishihara, Mamoru Yura, Masato Komori, Satoshi Egawa, Hideki Iijima, and Tetsuo Takehara, for the Osaka Gut Forum

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 7454

Thank you very much for your response regarding our manuscript entitled “A Comparative Study of Esomeprazole and Lansoprazole in Triple Therapy for Eradication of *Helicobacter pylori* in Japan”. We carefully examined comments and revised the manuscript. In re-reading, we noticed several points that we reconsidered to change and to touch up while these changes do not substantially affect. Point-to-point responses to the reviewers are attached for the convenience to the editor.

We used red font in a revised version. Please review our manuscript. We would be very happy if the revised manuscript would be found acceptable for publication in *World Journal of Gastroenterology*.

All authors take responsibility for the contents of the manuscript, and satisfy the requirements for authorship. The corresponding author can be reached at:

Tsutomu Nishida, MD

The manuscript has been improved according to the suggestions of reviewers:

First of all, thank you very much for your important and useful comments regarding our manuscript. Our responses to your comments are as follows:

Response to the reviewer 02810455 comment

Thank you for your suggestion. We would add more discussion about comparing the dose-dependency of both PPIs in Page 17, Line 10 in the revised manuscript as below .

Kirchheiner et al reported that the relative potencies of the PPIs compared to omeprazole based on mean 24-h gastric pH were 0.9 and 1.6 for lansoprazole and esomeprazole, respectively^[13]. Even though considering the difference of dose of each PPI in this study,

Minor points

We corrected some spelling errors that you pointed out.

Response to the reviewer 00044980 comment

Major comments

1. As you pointed, we added the definition of alcohol or drinking habit in Table 2. I added the following sentence in Discussion in Page 17, Line 15 in the revised manuscript as below.

One of the reasons is considered that esomeprazole is less likely to be affected than omeprazole by CYP2C19 polymorphisms ^[9].

Minor comments

1. As you pointed, I revised.
2. I added a review article including some reports comparing esomeprazole and omeprazole.
3. We corrected a spelling error that you pointed out.
4. I added % in age less than 40. I corrected some numbers of supplementary figures.

Response to the reviewer 02535953 comment

1. Thank you for your nice comments. We fully understand Maastricht consensus report that says clarithromycin containing triple therapy should not be considered the first line therapy for *H. pylori* eradication if clarithromycin resistance rate is over 15-20%. Unfortunately, Japanese health insurance dose not allowed other regimens but clarithromycin containing triple therapy even though we feel serious problem in our

region. Therefore those regimens containing clarithromycin are standard regimens as a first line eradication in Japan.

2. This dose was evaluated and suitable for the Japanese patients and this dose is allowed to use by Japanese health insurance. Therefore, this dose is a standard dose in Japan.
3. Thank for your nice comment, but this study is a prospective study. At first we did not include the recent use of antibiotics in the protocol. Therefore it is difficult to modify the exclusion criteria of the study later.
4. As you advise, we revised Table 2 using grading of compliance.
5. As you mentioned, it was a mistake. So I corrected it.

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*. We believe that the manuscript was significantly improved after the revision because of your comments. We hope that the revised manuscript is acceptable for publication in *World Journal of Gastroenterology*.

Sincerely yours,

Tetsuo Takehara, M.D., Ph.D.

Professor, Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine

2-2 Yamadaoka, Suita, Osaka 565-0871, Japan

Phone; +81-6-6879-3621

FAX, +81-6-6879-3629

E-mail: takehara@gh.med.osaka-u.ac.jp